Ekso Bionics Stock Intrinsic Value – EKSO BIONICS Reports Record-Breaking Revenue Despite Lower-Than-Expected Earnings
April 29, 2023
Trending News 🌥️
Ekso Bionics ($NASDAQ:EKSO) Holdings (EKSO) recently reported their financial results for the fiscal year, with a mixed performance. Despite exceeding the forecasted revenue by $1.3M, their GAAP earnings per share of -$0.33 fell short of expectation by $0.02. EKSO is a leading medical device company that specializes in the production of robotic exoskeletons for rehabilitation and industrial uses. EKSO’s high revenue of $4.1M this fiscal year is largely attributed to its new product launches, particularly the EksoNR exoskeleton, which is designed to help stroke patients achieve faster rehabilitation and recovery. Moreover, its EksoVest technology is being adopted by workers in the industrial sector and has been praised for increasing job safety and efficiency. On the other hand, the company’s lower-than-expected earnings is mainly due to the increasing costs associated with research and development of new products, as well as higher personnel expenses.
Additionally, their focus on expanding their business into international markets has also taken its toll. Overall, EKSO has reported record-breaking revenue despite the lower-than-expected earnings. It is clear that their innovative products have been well-received by both medical professionals and industrial users, and this trend is expected to continue in the future. With their strong portfolio of exoskeleton products and their focus on international expansion, EKSO stands poised to maintain its leading position in the medical devices industry.
Price History
EKSO BIONICS stock opened at $1.4 and closed at $1.4, up by 2.8% from its previous closing price of $1.4. Despite the lower-than-expected earnings, investors had confidence in the company’s long-term prospects, pushing the stock up slightly. Despite a soft quarter in terms of earnings, it is clear that the company has a bright future ahead of them with their well-received products and services. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Ekso Bionics. More…
| Total Revenues | Net Income | Net Margin |
| 12.91 | -15.08 | -121.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Ekso Bionics. More…
| Operations | Investing | Financing |
| -14.12 | -0.06 | 38.71 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Ekso Bionics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 40.9 | 15.46 | 2.18 |
Key Ratios Snapshot
Some of the financial key ratios for Ekso Bionics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -2.5% | – | -115.6% |
| FCF Margin | ROE | ROA |
| -110.4% | -34.5% | -22.8% |
Analysis – Ekso Bionics Stock Intrinsic Value
At GoodWhale, we have conducted an analysis of EKSO BIONICS‘s fundamentals and have found that their intrinsic value is around $4.0. Our proprietary Valuation Line was used to calculate the intrinsic value, and it indicates that the stock is currently undervalued by 64.9%, with the stock trading at $1.4. This represents a great opportunity for investors to get into EKSO BIONICS at a discounted price before the stock price rises to its true value. More…
Peers
– AngioDynamics Inc ($NASDAQ:ANGO)
AngioDynamics Inc is a medical device company that focuses on developing, manufacturing, and marketing innovative medical, surgical, and diagnostic devices used by healthcare professionals for the treatment of peripheral vascular disease, as well as tumors in the liver, kidney, and bone. As of 2023, AngioDynamics has a market capitalization of 325.27M. Its current Return on Equity is -5.72%. This suggests that AngioDynamics has not been successful in generating profits from its investments in the past few years. Despite this, the company continues to focus on providing innovative and effective solutions for its customers.
– Hogy Medical Co Ltd ($TSE:3593)
Hogy Medical Co Ltd is a healthcare company that provides healthcare products and services to the public. Founded in 2002, its market cap as of 2023 stands at 82.47B USD. Its Return on Equity (ROE) is 4.83%, which is an indication that the company is able to generate positive returns on the capital shareholders have provided. This is a positive sign for company performance and a sign of growth. Hogy Medical Co Ltd continues to expand its offerings and strives to provide quality healthcare products and services to its customers.
– Atrion Corp ($NASDAQ:ATRI)
Atrion Corp is a medical device company that specializes in ophthalmic, cardiovascular, and fluid delivery products. With a market cap of 1.09B as of 2023, Atrion Corp is a sizeable player in the medical device industry. Additionally, the company boasts a Return on Equity (ROE) of 10.21%, indicating that the company is performing better than its peers. This strong financial performance is indicative of the successful products and services that Atrion Corp provides to its customers.
Summary
However, the company reported total revenue of $4.1M, beating analyst estimates of $2.8M by $1.3M. This was a solid quarter for Ekso Bionics as it continues to make strides in the robotics field. Investors should consider Ekso Bionics as a potential long-term growth opportunity due to the improving fundamentals and attractive valuation metrics.
Related Posts
Recent Posts
